Fibrosis
is when connective tissue from an injury or other circumstances thickens and
scars, or when there is excess fibrous connective tissue in an organ after it
has been exposed to a chronic disease. Unfortunately, the effects of fibrosis
cannot be reversed, and there is currently no treatment that stops the disease
from getting worse, although some treatments can deal with the symptoms
temporarily.
Galectin
Therapeutics, Inc. (NASDAQ: GALT) is currently undertaking its phase 2a pilot
trial (NASHFX) with GR-MD-02 in non-alcoholic steatohepatitis (NASH) patients
with advanced fibrosis. Although the study did not meet original expectations,
Galectin’s larger scale, one year trial in patients with NASH cirrhosis has
already enrolled 162 subjects, and top line results will be reported by the end
of December 2017. The company considers it encouraging to see that GR-MD-02 has
an important clinical effect in both moderate and severe cases of psoriasis.
This further suggests that the substance can play a role for human diseases
that could be related to NASH.
Galectin
Therapeutics, Inc. is a biotechnology company focused on the science of
galectins, a family of proteins, and drug development. With this expertise, the
company creates new therapies for patients suffering from fibrotic diseases and
cancer. Galectin works with a variety of partners in order to achieve cost
effective and efficient development results within short time frames.
GALT
is currently looking to enhance and market its lead compounds in liver fibrosis
and cancer immunotherapies. The company has three key areas of focus: studying
galectins, developing proprietary compounds for diseases, and advancing its
discovery programs. All three work together in order to achieve the overall
goal of creating new therapies for fibrotic diseases and cancer.
For
more information, visit www.GalectinTherapeutics.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment